Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
DiaMedica Therapeutics Inc
DMAC
Healthcare
Biotechnology
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in...
patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:DMAC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(0)
•••
whoknows77
X
View Profile
View Bullboard History
Comment by
whoknows77
on Aug 14, 2019 5:59pm
RE:RE:No chinese money
This looks and feels like bad news. This damn company.
(71)
•••
StockscoutX
X
View Profile
View Bullboard History
Comment by
StockscoutX
on Aug 14, 2019 8:51am
RE:No chinese money
You can't trust Chinese to do business.
(2)
•••
Pugsrock2
X
View Profile
View Bullboard History
Post by
Pugsrock2
on Aug 13, 2019 6:32pm
No chinese money
Big surprise. Maybe they stole the technology or it doesnt work?
(99)
•••
RockLobster1
X
View Profile
View Bullboard History
Comment by
RockLobster1
on Aug 07, 2019 10:07am
RE:This stock is mainly and sparcely news driven for now.
does anyone have an approx idea of the next news expected? Looks like we could use it!
(71)
•••
StockscoutX
X
View Profile
View Bullboard History
Post by
StockscoutX
on Jul 11, 2019 4:15pm
This stock is mainly and sparcely news driven for now.
So far only good news when it comes out but not enough to maintain an upward trend. I think it will get more interesting in the weeks and months to come. eom.
(2)
•••
Pugsrock2
X
View Profile
View Bullboard History
Post by
Pugsrock2
on Jul 10, 2019 7:43pm
Smack down
US traders dont care about this company
(9)
•••
Winnipeg40
X
View Profile
View Bullboard History
Comment by
Winnipeg40
on Jun 22, 2019 10:17am
RE:Phase 2
From their conference call, they will be proceeding into a Ph 2. There are some steps to do, that should take a few months...but in this type of study it will not be that long
(1)
•••
fillsy
X
View Profile
View Bullboard History
Post by
fillsy
on Jun 21, 2019 9:26pm
Phase 2
Question for the wiser ones on bio, once you have had an acceptable Ph1 sample (like us!), is it virtually automatic that Ph2 will proceed immediately or is there admin that needs to occur first
...more
(99)
•••
RockLobster1
X
View Profile
View Bullboard History
Post by
RockLobster1
on Jun 20, 2019 1:56pm
DiaMedica price target raised to $11 after phase 1b data
https://thefly.com/landingPageNews.php?id=2924823&headline=DMAC;RETA-DiaMedica-price-target-raised-to--after-phase-b-data-at-CraigHallum Craig-Hallum analyst Alexander Nowak said the
...more
(9)
•••
Winnipeg40
X
View Profile
View Bullboard History
Comment by
Winnipeg40
on Jun 20, 2019 1:38pm
RE:RE:RE:RE:An update
Didnt need to post TODAY...as I posted yesterday. The NO increase is so meaningful....ask any nephrologist. and the increase in other markers make this spectacular. IMHO this Co. on this
...more
(99)
•••
RockLobster1
X
View Profile
View Bullboard History
Comment by
RockLobster1
on Jun 20, 2019 12:53pm
RE:RE:RE:RE:An update
fyi the webcast is onlline and presentation https://ir.diamedica.com/events-and-presentations
(99)
•••
RockLobster1
X
View Profile
View Bullboard History
Comment by
RockLobster1
on Jun 20, 2019 12:46pm
RE:RE:RE:An update
Did anyone listen to the call? Amazed no posting here today, we have over 3m shares traded so far, on dec 7 with that big drop we had 1m. Initial only, but seems like a game changer possibly.
...more
(9)
•••
Winnipeg40
X
View Profile
View Bullboard History
Comment by
Winnipeg40
on Jun 19, 2019 10:44pm
RE:RE:An update
These preliminary results are very exciting. I can see why they are holding a call tomorrow morning..The massive increase in NO is very encouraging.
(1499)
•••
Pandora
X
View Profile
View Bullboard History
Comment by
Pandora
on Jun 19, 2019 4:42pm
RE:An update
Well, if nothing else it caused a 50 cent bump initially in after hours trading on the Nasdaq.
(1499)
•••
Pandora
X
View Profile
View Bullboard History
Post by
Pandora
on Jun 19, 2019 4:26pm
An update
Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants DMAC | 21 minutes ago Favorable DM199 safety profile across tested doses
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Nanalysis Scientific Corp. Announces First Quarter 2024 Results
This Small-Cap Gold Stock Jumped Almost 50% on Friday